title: Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A.
abstract: The biochemical, electrophysiological and behavioural effects of SR 31742A, a novel and selective ligand of sigma sites in brain, labelled with (+)-[3H]3PPP (Ki = 5.3 +/- 0.3 nM), were investigated in rodents and compared with those of DA antagonists having (haloperidol) or not (spiroperidol) a high affinity for sigma sites. Like haloperidol but unlike spiroperidol, SR 31742A, (ED50 = 0.065 mg/kg, i.p., and 0.21 mg/kg, p.o.) antagonized sigma-dependent turning behaviour in mice and inhibited (0.5 mg/kg, i.v.) the spontaneous firing of hippocampal (CA3) neurones in urethane-anaesthetized rats. In chloral hydrate-anaesthetized rats, like classical antipsychotic compounds, SR 31742A (0.625-5 mg/kg, i.p.) increased the number of spontaneously active A9 and A10 DA cells after single administration and produced an opposite effect after repeated injections. The drug SR 31742A reduced (2.5, 5, 10 mg/kg, i.p.) the hyperactivity elicited by various drugs including that produced by injection of (+)-amphetamine into the nucleus accumbens and impaired avoidance responses at doses (5, 10 mg/kg, i.p.), sparing escape behaviour. SR 31742A lacked affinity for DA receptors and neither did the compound induce catalepsy nor antagonize such effects elicited by apomorphine as climbing, hypothermia, stereotypy or the inhibition of firing of DA neurones. SR 31742A did not affect the basal metabolism of DA but at 10 mg/kg (i.p.) it significantly reduced the amphetamine-induced rise in levels of 3-MT in the striatum of mice. Together, these results indicate a modulatory role for sigma sites upon the activity of hippocampal and DA systems and that sigma ligands exert effects, which suggest antipsychotic potential.
authors.affiliation: Sanofi Recherche, Neuropsychiatry Department, Montpellier, France.
authors.forename: M
authors.initials: M
authors.lastname: Poncelet
authors.forename: V
authors.initials: V
authors.lastname: Santucci
authors.forename: R
authors.initials: R
authors.lastname: Paul
authors.forename: C
authors.initials: C
authors.lastname: Gueudet
authors.forename: S
authors.initials: S
authors.lastname: Lavastre
authors.forename: J
authors.initials: J
authors.lastname: Guitard
authors.forename: R
authors.initials: R
authors.lastname: Steinberg
authors.forename: J P
authors.initials: JP
authors.lastname: Terranova
authors.forename: J C
authors.initials: JC
authors.lastname: Brelière
authors.forename: P
authors.initials: P
authors.lastname: Soubrié
mesh_terms: D000818:Animals; D001381:Azepines / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D005260:Female; D007700:Kinetics; D008297:Male; D051379:Mice; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D017480:Receptors, sigma / Q000187:drug effects*
chemical_list: D001381:Azepines; D017480:Receptors, sigma; C080238:3-(hexahydroazepin-1-yl)-1-(3-chloro-4-cyclohexylphenyl)-1-propene hydrochloride